ORY Oryzon Genomics S.A.

2.687USD2.450 EUR · BME+5.51%Mkt Cap: 220.23M USDP/E: —

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hemato…